Display Settings:

Format

Send to:

Choose Destination
    Eur J Med Chem. 2009 Oct;44(10):4098-106. Epub 2009 May 13.

    Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.

    Source

    Johnson & Johnson Pharmaceutical Research & Development, LLC, San Diego, CA 92121, USA. cdvorak@its.jnj.com

    Abstract

    A series of (4-aminobutyn-1-yl)benzylamines were prepared and the SAR around three key areas: (1) the amine attached to the butynyl linker (R(3)R(4)N-); (2) the benzylamine moiety (R(1)R(2)N-); and (3) the point of attachment of the benzylamine group (R(1)R(2)N- in the ortho, meta, or para positions) was examined. One compound, 4-[3-(4-piperidin-1-yl-but-1-ynyl)-benzyl]-morpholine (9s) was chosen for further profiling and found to be a selective histamine H(3) antagonist with desirable drug-like properties. Ex vivo receptor occupancy studies established that 9s does occupy H(3) binding sites in the brain of rats after oral administration. Subcutaneous doses of 9s (10mg/kg) given during the natural sleep phase demonstrated robust wake-promoting effects.

    PMID:
    19524331
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk